You are probably right. The fact that they are doi
Post# of 148183
(Total Views: 509)
Posted On: 09/06/2019 5:04:57 AM
You are probably right. The fact that they are doing a live stream of the meeting might point to this. Hopeful that they announce something solid, not non-binding termsheets on the table and a deal any day now soon.
CytoDyn Announces Webcast for its Annual Meeting of Stockholders
Download as PDFSeptember 06, 2019 5:00am EDT
VANCOUVER, Washington, Sept. 06, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its annual meeting of stockholders on September 12, 2019 will be shared live through a webcast that will allow access to the audio portion of the meeting, along with management’s presentation.
Nader Pourhassan, Ph.D., President and CEO will provide an update on several initiatives, including BLA filing timeline, along with licensing and partnering opportunities. Dr. Pourhassan will also be joined by Jonah Sacha, Ph.D., Senior Science Advisor to the Company, who will discuss his research with leronlimab (PRO 140) as a potential therapeutic for HIV Pre-Exposure Prophylaxis (PrEP) and HIV cure. Dr. Sacha is an expert in HIV/AIDS research who serves on the National Institutes of Health Office of AIDS Research Advisory Council and leads a research laboratory in the Vaccine and Gene Therapy Institute and Oregon National Primate Research Center at the Oregon Health & Science University. In addition, Bruce Patterson, M.D., currently CEO and Founder of IncellDx, and former Medical Director of Virology at Stanford University Hospitals and Clinics, will comment on the role of targeting CCR5 for potential therapeutics and the recent agreement between IncellDX and CytoDyn.
Date: Thursday, September 12, 2019
Time: 9:30 a.m. PT / 12:30 p.m. ET
Dial In: For audio: 877-407-2986 or 201-378-4916
CytoDyn Announces Webcast for its Annual Meeting of Stockholders
Download as PDFSeptember 06, 2019 5:00am EDT
VANCOUVER, Washington, Sept. 06, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its annual meeting of stockholders on September 12, 2019 will be shared live through a webcast that will allow access to the audio portion of the meeting, along with management’s presentation.
Nader Pourhassan, Ph.D., President and CEO will provide an update on several initiatives, including BLA filing timeline, along with licensing and partnering opportunities. Dr. Pourhassan will also be joined by Jonah Sacha, Ph.D., Senior Science Advisor to the Company, who will discuss his research with leronlimab (PRO 140) as a potential therapeutic for HIV Pre-Exposure Prophylaxis (PrEP) and HIV cure. Dr. Sacha is an expert in HIV/AIDS research who serves on the National Institutes of Health Office of AIDS Research Advisory Council and leads a research laboratory in the Vaccine and Gene Therapy Institute and Oregon National Primate Research Center at the Oregon Health & Science University. In addition, Bruce Patterson, M.D., currently CEO and Founder of IncellDx, and former Medical Director of Virology at Stanford University Hospitals and Clinics, will comment on the role of targeting CCR5 for potential therapeutics and the recent agreement between IncellDX and CytoDyn.
Date: Thursday, September 12, 2019
Time: 9:30 a.m. PT / 12:30 p.m. ET
Dial In: For audio: 877-407-2986 or 201-378-4916
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼